Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
Conditions
Interventions
OM336
Start Date
November 1, 2025
Primary Completion Date
June 1, 2027
Completion Date
March 1, 2028
Last Updated
November 14, 2025
NCT06991114
NCT06888960
NCT07085676
NCT07072884
NCT02915159
Lead Sponsor
Ouro Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions